{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:08:39Z","timestamp":1778868519518,"version":"3.51.4"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"\n Background<\/jats:title>\n The present study evaluated the real-world experience with cyclin dependent kinase 4\/6 inhibitors palbociclib and ribociclib in hormone receptor-positive\/ human epidermal growth factor receptor 2-negative (HR\u2009+\u2009\/HER2-) metastatic breast cancer.<\/jats:p>\n <\/jats:sec>\n \n Method<\/jats:title>\n This study was conducted on the HR\u2009+\u2009\/HER2- metastatic breast cancer patients who received palbociclib\/ ribociclib in the first line or recurrent setting between January 2021 and January 2023 along with endocrine therapy. Data was retrieved from the Hospital medical records.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In the patients receiving palbociclib, a better median progression free survival (PFS) was observed in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 (27.3 months,p-value <0.0001),\n de novo<\/jats:italic>\n disease (17.5 months,p-value 0.0155), first line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (20.3 months,p-value 0.0001). Similarly, in the patients receiving ribociclib, a better median PFS was observed in patients with ECOG PS 1 (22.2 months,p-value <0.0001),\n de novo<\/jats:italic>\n disease (21.7 months,p-value 0.0042), first-line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (21.7 months,p-value <0.0001). On multivariate analysis, ECOG PS, line of hormone therapy and prior chemotherapy showed significance (p-values <0.0001,\u2009<\u20090.0001 & 0.0269, respectively).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The study shows real-world experience with cyclin dependent kinase 4\/6 inhibitors palbociclib and ribociclib in metastatic breast cancer in India.<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0349196","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:21:34Z","timestamp":1778865694000},"page":"e0349196","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real world experience with cyclin dependent kinase inhibitors in metastatic breast cancer in India"],"prefix":"10.1371","volume":"21","author":[{"given":"Anindya","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupal","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ullas","family":"Batra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vineet","family":"Talwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shekhar","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha","family":"Bothra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaturbhuj","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swati","family":"Chugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6191-563X","authenticated-orcid":true,"given":"Dinesh Chandra","family":"Doval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"pone.0349196.ref001","unstructured":"National Cancer Institute. Cancer Stat Facts: Female Breast Cancer Subtypes. https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html. Accessed 2022 December 23."},{"issue":"3","key":"pone.0349196.ref002","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast Cancer Treatment: A Review","volume":"321","author":"AG Waks","year":"2019","journal-title":"JAMA"},{"key":"pone.0349196.ref003","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040","volume":"66","author":"M Arnold","year":"2022","journal-title":"Breast"},{"key":"pone.0349196.ref004","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4103\/ijmr.ijmr_1821_22","article-title":"Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India","volume":"156","author":"K Sathishkumar","year":"2022","journal-title":"Indian J Med Res"},{"key":"pone.0349196.ref005","unstructured":"Cancer Institute N. SEER data. https:\/\/www.cancer.org\/cancer\/breast-cancer\/understanding-a-breast-cancer-diagnosis\/breast-cancer-survival-rates.html. 2020. Accessed 2022 December 23."},{"issue":"10","key":"pone.0349196.ref006","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","volume":"386","author":"GN Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"pone.0349196.ref007","article-title":"Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer (ER+\/HER2\u2212 ABC): Analyses from PALOMA-2","volume":"40","author":"RS Finn","year":"2022","journal-title":"JCO"},{"issue":"5","key":"pone.0349196.ref008","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+\/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial","volume":"28","author":"Y-S Lu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"pone.0349196.ref009","doi-asserted-by":"crossref","unstructured":"Cristofanili M, Rugo HS, Im SA, et al. Overall survival with palbociclib and fulvestrant in women with HR+\/ HER2- ABC: updated exploratory analyses of PALOMA-3, a double-blind phase III randomized study. Clin Cancer Res. 2022;28(16):3433\u201342.","DOI":"10.1158\/1078-0432.CCR-22-0305"},{"key":"pone.0349196.ref010","article-title":"Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR \/HER2? Advanced breast cancer (ABC) treated with ribociclib (RIB) fulvestrant (FUL)","volume":"33","author":"A Cecala","year":"2022","journal-title":"Ann Oncol"},{"issue":"20","key":"pone.0349196.ref011","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer","volume":"379","author":"NC Turner","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0349196.ref012","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer","volume":"382","author":"DJ Slamon","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0349196.ref013","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.08.009","article-title":"LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)","volume":"33","author":"MP Goetz","year":"2022","journal-title":"Annals of Oncology"},{"key":"pone.0349196.ref014","article-title":"Final overall survival analysis of Monarch 2: A phase 3 trial of Abemaciclib plus Fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer","volume":"83","author":"GW Sledge Jr","year":"2023","journal-title":"Cancer Res"},{"key":"pone.0349196.ref015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"S Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"pone.0349196.ref016","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/jnci\/djaa071","article-title":"Overall Survival of CDK4\/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis","volume":"112","author":"F Schettini","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"pone.0349196.ref017","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.3390\/ijms21176400","article-title":"Progression-Free Survival and Overall Survival of CDK 4\/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis","volume":"21","author":"M Piezzo","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"pone.0349196.ref018","doi-asserted-by":"crossref","first-page":"100332","DOI":"10.1016\/j.esmoop.2021.100332","article-title":"Systematic review and meta-analysis of post-progression outcomes in ER+\/HER2- metastatic breast cancer after CDK4\/6 inhibitors within randomized clinical trials","volume":"6","author":"E Munzone","year":"2021","journal-title":"ESMO Open"},{"issue":"20","key":"pone.0349196.ref019","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010746","article-title":"The CDK4\/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis","volume":"97","author":"W Ding","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"pone.0349196.ref020","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10549-019-05133-y","article-title":"Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials","volume":"174","author":"F Petrelli","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"pone.0349196.ref021","article-title":"Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis","volume":"3","author":"J Li","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"pone.0349196.ref022","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"pone.0349196.ref023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.25259\/IJMIO_24_2021","article-title":"Outcome in patients of hormone receptor (HR) positive (Her 2) negative metastatic breast cancer treated with palbociclib \u2013 A real-world experience","volume":"7","author":"A Bapna","year":"2022","journal-title":"IJMIO"},{"issue":"1","key":"pone.0349196.ref024","doi-asserted-by":"crossref","first-page":"16236","DOI":"10.1038\/s41598-021-95758-1","article-title":"Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population","volume":"11","author":"C Agrawal","year":"2021","journal-title":"Sci Rep"},{"issue":"16","key":"pone.0349196.ref025","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2217\/fon-2020-1264","article-title":"CDK4\/6 inhibitors in HR+\/HER2- advanced\/metastatic breast cancer: a systematic literature review of real-world evidence studies","volume":"17","author":"N Harbeck","year":"2021","journal-title":"Future Oncol"},{"issue":"24","key":"pone.0349196.ref026","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3","volume":"36","author":"DJ Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"18","key":"pone.0349196.ref027","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","volume":"375","author":"GN Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0349196.ref028","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/curroncol29020089","article-title":"Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced\/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network","volume":"29","author":"JW Law","year":"2022","journal-title":"Curr Oncol"},{"key":"pone.0349196.ref029","article-title":"Real-World Outcomes With CDK4\/6 Inhibitors Are Similar to Those in Clinical Trials for HR-Positive Breast Cancer","author":"P Reddy","year":"2022","journal-title":"ASCO"},{"key":"pone.0349196.ref030","author":"D Luftner","year":"2022"},{"issue":"4","key":"pone.0349196.ref031","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000774","article-title":"Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group","volume":"5","author":"E Fountzilas","year":"2020","journal-title":"ESMO Open"},{"key":"pone.0349196.ref032","doi-asserted-by":"crossref","first-page":"100985","DOI":"10.1016\/j.eclinm.2021.100985","article-title":"Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns","volume":"38","author":"SM Lima","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"7","key":"pone.0349196.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253722","article-title":"Efficacy and safety of palbociclib and ribociclib in patients with estrogen and\/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice","volume":"16","author":"S Rath","year":"2021","journal-title":"PLoS One"},{"issue":"8","key":"pone.0349196.ref034","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.clbc.2022.08.011","article-title":"Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer","volume":"22","author":"V Wong","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"pone.0349196.ref035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.breast.2020.11.008","article-title":"Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer","volume":"54","author":"B Porte","year":"2020","journal-title":"Breast"},{"issue":"1","key":"pone.0349196.ref036","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13058-021-01409-8","article-title":"Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+\/HER2- metastatic breast cancer in US real-world clinical practice","volume":"23","author":"A DeMichele","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"1","key":"pone.0349196.ref037","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41523-022-00479-x","article-title":"Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+\/HER2- metastatic breast cancer","volume":"8","author":"HS Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"7","key":"pone.0349196.ref038","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"GN Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"pone.0349196.ref039","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"D Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"pone.0349196.ref040","first-page":"1","article-title":"Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study","volume":"5","author":"S-A Im","year":"2019","journal-title":"J Glob Oncol"},{"issue":"3","key":"pone.0349196.ref041","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3390\/curroncol28030209","article-title":"First-Line Treatment with a Cyclin-Dependent Kinase 4\/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta","volume":"28","author":"CP Amaro","year":"2021","journal-title":"Curr Oncol"},{"issue":"4","key":"pone.0349196.ref042","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"M Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"pone.0349196.ref043","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz242.022","article-title":"Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis","volume":"30","author":"M Torres","year":"2019","journal-title":"Annals of Oncology"},{"key":"pone.0349196.ref044","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e13031","article-title":"Real-world outcomes from the systemic use of CDK 4\/6 inhibitors (CDKIs) in the management of ER positive (+) HER2 negative (-) metastatic breast cancer (mBC)","volume":"39","author":"K DeSouza","year":"2021","journal-title":"JCO"},{"issue":"8","key":"pone.0349196.ref045","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/oncolo\/oyac089","article-title":"Real-World Experience with CDK4\/6 Inhibitors for Metastatic HR+\/HER2- Breast Cancer at a Single Cancer Center","volume":"27","author":"ES Knudsen","year":"2022","journal-title":"Oncologist"},{"key":"pone.0349196.ref046","first-page":"101","article-title":"Ribociclib in the Treatment of Hormone-Receptor Positive\/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection","volume":"14","author":"MC Parati","year":"2022","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"pone.0349196.ref047","doi-asserted-by":"crossref","first-page":"100268","DOI":"10.1016\/j.ejmcr.2025.100268","article-title":"Nanotechnology-based drug delivery for breast cancer treatment: Current applications and future directions","volume":"14","author":"MA Samad","year":"2025","journal-title":"European J Medicinal Chemistry Reports"},{"key":"pone.0349196.ref048","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.semcancer.2019.08.005","article-title":"Recent nanotechnological interventions targeting PI3K\/Akt\/mTOR pathway: A focus on breast cancer","volume":"59","author":"V Sharma","year":"2019","journal-title":"Semin Cancer Biol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:21:43Z","timestamp":1778865703000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349196"}},"subtitle":[],"editor":[{"given":"Avaniyapuram Kannan","family":"Murugan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0349196","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}